SCHEMBL4147946

SCHEMBL4147946

Cc1ccc(N2CCN(Cc3nc4ccccc4n3C)CC2)cc1

nearest known ligand 0.83

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 13/20 0.83
DRD4 P21917 9/20 0.80
LMNA P02545 5/20 0.80
GAA P10253 3/20 0.80
SMN1; SMN2 Q16637 3/20 0.80
POLB P06746 1/20 0.80
MAPK1 P28482 1/20 0.80
MAPT P10636 3/20 0.76
GFER P55789 1/20 0.76
KDM4E B2RXH2 2/20 0.69
ALDH1A1 P00352 2/20 0.69
HTT P42858 2/20 0.69
HPGD P15428 1/20 0.69
L3MBTL1 Q9Y468 1/20 0.69
OPRM1 P35372 1/20 0.67
OPRD1 P41143 1/20 0.67
NPSR1 Q6W5P4 1/20 0.66
DRD2 P14416 3/20 0.57
DRD3 P35462 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467817 0.93 GRM2 (0.72) GRM2DRD4LMNAGAASMN1; SMN2
SCHEMBL4138559 0.91 GRM2 (1.00) GRM2DRD4LMNAGAASMN1; SMN2
SCHEMBL4151775 0.89 GRM2 (0.81) GRM2DRD4LMNAGAASMN1; SMN2
SCHEMBL4139747 0.89 GRM2 (1.00) GRM2DRD4LMNAGAASMN1; SMN2
SCHEMBL4146837 0.86 LMNA (1.00) GRM2DRD4LMNAGAASMN1; SMN2
SCHEMBL4138550 0.86 GRM2 (0.77) GRM2DRD4LMNAGAASMN1; SMN2
SCHEMBL5156990 0.86 GRM2 (0.81) GRM2DRD4LMNAGAASMN1; SMN2
SCHEMBL15453987 0.86 LMNA (0.64) GRM2DRD4LMNAGAASMN1; SMN2
SCHEMBL15467819 0.83 GRM2 (0.68) GRM2DRD4LMNAGAASMN1; SMN2
SCHEMBL4144234 0.83 GRM2 (0.77) GRM2DRD4LMNAGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US claimed
EP-2004613-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS AstraZeneca AB (SE) 2008-12-24 EP claimed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 WO claimed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators ASTRAZENECA AB (SE) 2009-07-30 US disclosed
WO-2007115077-A2 BICYCLIC BENZIMIDAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192169-A1 Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators GRM1, GRIN1, GRM2 GRM2 3/4885DRD4 205/4885LMNA 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.